Preparedness for Future Pandemics Using a Highly Effective Recombinant Vesicular Stomatitis Virus-Based Vaccine Platform Technology: Strategies for Developing Superior Vaccines
Main Article Content
Abstract
We have developed highly effective, avirulent vesicular stomatitis virus (VSV) vectors to create potent recombinant viral vector-based vaccines. These vaccines induce both humoral and cellular immune responses. For developing a safe and effective viral vector vaccine, we chose VSV because of its broad host range and efficient replication. To enhance the safety of the rVSV vector, we introduced mutations in the M gene to attenuate it, since the VSV M protein is responsible for VSV-induced pathogenesis. The combined mutations G21E, M51R, and L111F (GML) in the M protein of the Indiana serotype of VSV (VSVInd-GML), along with mutations G22E, M48R, and M51R (GMM), and G22E, M48R, M51R, and L110F (GMML) in the M protein of VSV New Jersey serotype (VSVNJ), were used to generate VSVNJ-GMM and VSVNJ-GMML, respectively. The rVSVInd-GML, rVSVNJ-GMM, and rVSVNJ-GMML exhibited reduced cytopathic effects in vitro and across various animal species. Animals injected with up to 5 billion live M gene mutant VSV showed no significant adverse effects, whereas only 1,000 wild-type VSV were enough to kill mice within four days.
All future pandemics are likely caused by airborne enveloped RNA viruses that feature surface glycoproteins on their virions. An effective signal peptide at the N-terminus of all glycoproteins is crucial for efficient synthesis, proper processing, glycosylation, intracellular transport, and secretion. Therefore, we replaced the natural signal peptides of viral glycoproteins with a highly efficient signal peptide from honeybee melittin, known for its effectiveness in glycoprotein biosynthesis and intracellular transport. Additionally, we attached the transmembrane domain and cytoplasmic tail of VSV G protein (Gtc) to the C-terminus of the target glycoprotein to enhance its incorporation into pseudotype virions. To prevent vector immunity in booster immunization, we utilised two different serotypes of VSV, along with pseudotype virions carrying the VSV G protein and the glycoproteins of the target virus. These pseudovirions will bind to the VSV receptor, low-density lipoprotein (LDL) receptor, and the receptors of the target surface glycoprotein to initiate infection.
The M gene mutants of VSVInd and VSVNJ vectors, which carry surface glycoprotein genes from target viruses, stimulate strong humoral and cellular immune responses and protect animals from challenges with wild-type viruses. These M gene mutant vectors are ideal for developing vaccines to fight future pandemics.
This article explains how to develop an effective vaccine for future pandemics caused by enveloped RNA viruses.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Hilleman MR, Ellis R. Vaccines made from recombinant yeast cells. Vaccine. Jun 1986;4(2):75-6. doi:10.1016/0264-410x(86)90040-x
3. Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses. Jan 21 2020;12(2)doi:10.3390/v12020126
4. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). Jul 16 2020;8(3)doi:10.3390/vaccines8030391
5. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. Jan 1999;73(1):251-9. doi:10.1128/JVI.73.1.251-259.1999
6. Kim GN, Wu, K., and Kang, C.-Y. Establishment of Chinese Hamster ovary (CHO) cells expressing T7 RNA polymerase constitutively. Manuscript in preparation. 2025;
7. Lyles DS, Rupprecht, C.E. . Fields Virology vol 1. Rhabdoviridae. Lippincott Williams & Wilkins, a Wolters Kluwer business; 2007.
8. An HY, Kim GN, Wu K, Kang CY. Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression. Virus Res. Jan 2013;171(1):168-77. doi:10.1016/j.virusres.2012.11.007
9. Whitt MA. Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods. Nov 2010;169(2):365-74. doi:10.1016/j.jviromet.2010.08.006
10. Miyanohara A. Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer. Cold Spring Harb Protoc. Apr 1 2012;2012(4):453-6. doi:10.1101/pdb.prot068528
11. Clarke DK, Nasar F, Lee M, et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol. Feb 2007;81(4):2056-64. doi:10.1128/JVI.01911-06
12. Lu M, Zhang Y, Dravid P, et al. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. Sep 27 2021;95(20):e0059221. doi:10.1128/JVI.00592-21
13. Choi JA, Wu K, Kim GN, et al. Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene. J Gen Virol. Apr 2021;102(4)doi:10.1099/jgv.0.001588
14. Kim GN, Choi JA, Wu K, et al. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathog. Dec 2021;17(12): e1010092. doi:10.1371/journal.ppat.1010092
15. Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. Nov 2011;204 Suppl 3(Suppl 3):S1066-74. doi:10.1093/infdis/jir348
16. Black BL, Lyles DS. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol. Jul 1992;66(7):4058-64. doi:10.1128/JVI.66.7.4058-4064.1992
17. Her LS, Lund E, Dahlberg JE. Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science. Jun 20 1997;276(5320):1845-8. doi:10.1126/science.276.5320.1845
18. Blondel D, Harmison GG, Schubert M. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J Virol. Apr 1990;64(4):1716-25. doi:10.1128/JVI.64.4.1716-1725.1990
19. Melki R, Gaudin Y, Blondel D. Interaction between tubulin and the viral matrix protein of vesicular stomatitis virus: possible implications in the viral cytopathic effect. Virology. Jul 1994;202(1):339-47. doi:10.1006/viro.1994.1350
20. Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol. May 2003;77(9):5524-8. doi:10.1128/jvi.77.9.5524-5528.2003
21. Gill DS, Banerjee AK. Complete nucleotide sequence of the matrix protein mRNA of vesicular stomatitis virus (New Jersey serotype). Virology. Apr 15 1986;150(1):308-12. doi:10.1016/0042-6822(86) 90293-x
22. Coulon P, Deutsch V, Lafay F, et al. Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J Gen Virol. Apr 1990;71 ( Pt 4):991-6. doi:10.1099/0022-1317-71-4-991
23. Petersen JM, Her LS, Varvel V, Lund E, Dahlberg JE. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol. Nov 2000;20(22):8590-601. doi:10.1128/MCB.20.22.8590-8601.2000
24. von Kobbe C, van Deursen JM, Rodrigues JP, et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell. Nov 2000;6(5):1243-52. doi:10.1016/s1097-2765(00)00120-9
25. Petersen JM, Her LS, Dahlberg JE. Multiple vesiculoviral matrix proteins inhibit both nuclear export and import. Proc Natl Acad Sci U S A. Jul 17 2001;98(15):8590-5. doi:10.1073/pnas.151240998
26. Kim GN, Wu K, Hong JP, Awamleh Z, Kang CY. Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors. J Virol. Jun 2015;89(12):6338-51. doi:10.1128/JVI.00222-15